title: [Effects of proteasome inhibitors on leukemias].
abstract: The proteasome is primarily responsible for intracellular protein degradation. The abnormality of its activity is sign of tumorigenesis. It was confirmed that proteasome inhibitors have activities against a variety of malignancies. Bortezomib, the first proteasome inhibitor, obtained permission of clinical trial and on sale. Multiple myeloma patients treated with bortezomib have gained a high overall response rate and complete remission rate. A lot of studies on effects of proteasome inhibitors on leukemias, including plasma cell leukemia; chronic lymphocytic leukemia, adult T cell lymphoma/leukemia, chronic myeloid leukemia and acute myeloid leukemia, were reviewed in this article.
authors: Department of Hematology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, China.
authors: Shu-Qing
authors: SQ
authors: Lü
authors: Jian-Min
authors: JM
authors: Yang
authors: Jian-Min
authors: JM
authors: Wang
mesh_terms: D000818:Animals; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000201:enzymology*; D009101:Multiple Myeloma / Q000188:drug therapy; D011480:Protease Inhibitors / Q000627:therapeutic use*; D061988:Proteasome Inhibitors; D011719:Pyrazines / Q000627:therapeutic use
chemical_list: D001897:Boronic Acids; D011480:Protease Inhibitors; D061988:Proteasome Inhibitors; D011719:Pyrazines; D000069286:Bortezomib